Dextromethorphan as a potential neuroprotective agent with unique mechanisms of action

被引:72
作者
Werling, Linda L.
Lauterbach, Edward C.
Calef, Ursula
机构
[1] Calef Biomed Consulting, Laguna Beach, CA 92651 USA
[2] George Washington Univ, Med Ctr, Inst Biomed Sci, Washington, DC 20037 USA
[3] George Washington Univ, Med Ctr, Dept Pharmacol & Physiol, Washington, DC 20037 USA
[4] Mercer Univ, Sch Med, Div Adult & Geriatr Psychiat, Neurodegenerat Dis Program, Macon, GA 31207 USA
基金
巴西圣保罗研究基金会;
关键词
dextromethorphan; neuroprotective; low-affinity; uncompetitive NMDA receptor antagonist; sigma-1 receptor agonist; voltage-gated calcium channel antagonist;
D O I
10.1097/NRL.0b013e3180f60bd8
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: Dextromethorphan (DM) is a widely-used antitussive. DM's complex central nervous system (CNS) pharmacology became of interest when it was discovered to be neuroprotective due to its low-affinity, uncompetitive N-methyl-D-aspartate (NMDA) receptor antagonism. Review Summary: Mounting preclinical evidence has proven that DM has important neuroprotective properties in various CNS injury models, including focal and global ischemia, seizure, and traumatic brain injury paradigms. Many of these protective actions seem functionally related to its inhibitory effects on glutamate-induced neurotoxicity via NMDA receptor antagonist, sigma-1 receptor agonist, and voltage-gated calcium channel antagonist actions. DM's protection of dopamine neurons in parkinsonian models may be due to inhibition of neurodegenerative inflammatory responses. Clinical findings are limited, with preliminary evidence indicating that DM protects against neuronal damage. Negative findings seem to relate to attainment of inadequate DM brain concentrations. Small studies have shown some promise for treatment of perioperative brain injury, amyotrophic lateral sclerosis, and symptoms of methotrexate neurotoxicity. DM safety/tolerability trials in stroke, neurosurgery, and amyotrophic lateral sclerosis patients demonstrated a favorable safety profile. DM's limited clinical benefit is proposed to be associated with its rapid metabolism to dextrorphan, which restricts its central bioavailability and therapeutic utility. Systemic concentrations of DM can be increased via coadministration of low-dose quinidine (Q), which reversibly inhibits its first-pass elimination. Potential drug interactions with DM/Q are discussed. Conclusions: Given the compelling preclinical evidence for neuroprotective properties of DM, initial clinical neuroprotective findings, and clinical demonstrations that the DM/Q combination is well tolerated, this strategy may hold promise for the treatment of various acute and degenerative neurologic disorders.
引用
收藏
页码:272 / 293
页数:22
相关论文
共 121 条
[1]   SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF THE N-METHYL-D-ASPARTATE ANTAGONIST DEXTRORPHAN IN PATIENTS WITH ACUTE STROKE [J].
ALBERS, GW ;
ATKINSON, RP ;
KELLEY, RE ;
ROSENBAUM, DM .
STROKE, 1995, 26 (02) :254-258
[2]   SAFETY AND TOLERANCE OF ORAL DEXTROMETHORPHAN IN PATIENTS AT RISK FOR BRAIN ISCHEMIA [J].
ALBERS, GW ;
SAENZ, RE ;
MOSES, JA ;
CHOI, DW .
STROKE, 1991, 22 (08) :1075-1077
[3]   TOLERABILITY OF ORAL DEXTROMETHORPHAN IN PATIENTS WITH A HISTORY OF BRAIN ISCHEMIA [J].
ALBERS, GW ;
SAENZ, RE ;
MOSES, JA .
CLINICAL NEUROPHARMACOLOGY, 1992, 15 (06) :509-514
[4]   NONOPIOID ANTITUSSIVES INHIBIT ENDOGENOUS GLUTAMATE RELEASE FROM RABBIT HIPPOCAMPAL SLICES [J].
ANNELS, SJ ;
ELLIS, Y ;
DAVIES, JA .
BRAIN RESEARCH, 1991, 564 (02) :341-343
[5]  
[Anonymous], NEUROLOGY
[6]   A PILOT TRIAL OF DEXTROMETHORPHAN IN AMYOTROPHIC-LATERAL-SCLEROSIS [J].
ASKMARK, H ;
AQUILONIUS, SM ;
GILLBERG, PG ;
LIEDHOLM, LJ ;
STALBERG, E ;
WUOPIO, R .
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 1993, 56 (02) :197-200
[7]   Neuropeptide Y mediated enhancement of NMDA-stimulated [3H]dopamine release from rat prefrontal cortex is reversed by σ1 receptor antagonists [J].
Ault, DT ;
Werling, LL .
SCHIZOPHRENIA RESEARCH, 1998, 31 (01) :27-36
[8]  
Berman F W, 1996, J Biochem Toxicol, V11, P217, DOI 10.1002/(SICI)1522-7146(1996)11:5<217::AID-JBT2>3.3.CO
[9]  
2-B
[10]  
Berman FW, 1999, J PHARMACOL EXP THER, V290, P439